AR037627A1 - Composicion farmaceutica en forma de dosificacion solida para su administracion oral y uso de dicha composicion farmaceutica y de un componente basico de una pareja efervescente para la fabricacion de un medicamento - Google Patents
Composicion farmaceutica en forma de dosificacion solida para su administracion oral y uso de dicha composicion farmaceutica y de un componente basico de una pareja efervescente para la fabricacion de un medicamentoInfo
- Publication number
- AR037627A1 AR037627A1 ARP020104674A ARP020104674A AR037627A1 AR 037627 A1 AR037627 A1 AR 037627A1 AR P020104674 A ARP020104674 A AR P020104674A AR P020104674 A ARP020104674 A AR P020104674A AR 037627 A1 AR037627 A1 AR 037627A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- headache
- weight
- manufacture
- oral administration
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 206010019233 Headaches Diseases 0.000 abstract 5
- 231100000869 headache Toxicity 0.000 abstract 5
- 102000035038 5-HT1 receptors Human genes 0.000 abstract 2
- 108091005478 5-HT1 receptors Proteins 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000000018 receptor agonist Substances 0.000 abstract 2
- 229940044601 receptor agonist Drugs 0.000 abstract 2
- 206010009094 Chronic paroxysmal hemicrania Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010043269 Tension headache Diseases 0.000 abstract 1
- 208000008548 Tension-Type Headache Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 238000005213 imbibition Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000007777 paroxysmal Hemicrania Diseases 0.000 abstract 1
- 230000001739 rebound effect Effects 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical group CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 abstract 1
- 229960003708 sumatriptan Drugs 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición farmacéutica en forma de dosificación sólida para su administración oral, capaz de una rápida desintegración y dispersión dentro del tracto gastrointestinal, que comprende un compuesto que actúa como agonista del receptor 5HT1 o uno de sus derivados farmacéuticamente aceptable como ingrediente activo, en la que más de del 70% preferentemente más de 80%, más preferentemente más del 90% del ingrediente activo se disuelve en fluido gástrico simulado (SGF) durante cinco minutos en un aparato USPII de 10 rpm de velocidad de discriminación de las paletas. El uso de dicha composición farmacéutica para la fabricación de un medicamento para tratar estados asociados al dolor cefálico tal como dolor de cabeza en racimos, hemicránea paroxistica crónica, dolor de cabeza asociado a trastornos vasculares, dolor de cabeza asociado a substancias o a su supresión, dolor de cabeza por efecto rebote, dolor de cabeza de tensión y, en particular migrana. Uso de un componente básico de una pareja efervescente que comprende de 5 a 50% en peso, un desintegrante que comprende de 0,5 a 10% en peso, y una carga insoluble que comprende de alrededor de 30 a 99% en peso que incluye un agente de imbibición que él mismo comprende de alrededor de 1 a alrededor de 99% en peso, basado en el peso en seco de la forma de dosificación, para la preparación de la composición farmacéutica. Reivindicación 12: una composición según una cualquiera de las reivindicaciones 1 a 11, caracterizada por que el agonista del receptor 5HT1, es sumatriptan o uno de sus derivados farmacéuticos aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0129117.8A GB0129117D0 (en) | 2001-12-05 | 2001-12-05 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037627A1 true AR037627A1 (es) | 2004-11-17 |
Family
ID=9927051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104674A AR037627A1 (es) | 2001-12-05 | 2002-12-03 | Composicion farmaceutica en forma de dosificacion solida para su administracion oral y uso de dicha composicion farmaceutica y de un componente basico de una pareja efervescente para la fabricacion de un medicamento |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20050032867A1 (es) |
| EP (2) | EP1450770B1 (es) |
| JP (1) | JP3699969B2 (es) |
| KR (1) | KR100591237B1 (es) |
| CN (1) | CN1289069C (es) |
| AR (1) | AR037627A1 (es) |
| AT (1) | ATE291900T1 (es) |
| AU (1) | AU2002358602B2 (es) |
| BR (1) | BR0214497A (es) |
| CA (1) | CA2469019C (es) |
| CO (1) | CO5580741A2 (es) |
| DE (1) | DE60203537T2 (es) |
| ES (1) | ES2236608T3 (es) |
| FI (1) | FI20022128A7 (es) |
| GB (1) | GB0129117D0 (es) |
| HU (1) | HU229313B1 (es) |
| IL (1) | IL161997A (es) |
| IS (1) | IS2481B (es) |
| MX (1) | MXPA04005420A (es) |
| MY (1) | MY129314A (es) |
| NO (1) | NO329896B1 (es) |
| NZ (1) | NZ532829A (es) |
| PL (1) | PL194702B1 (es) |
| PT (1) | PT1450770E (es) |
| RU (1) | RU2285526C2 (es) |
| TW (1) | TWI240638B (es) |
| WO (1) | WO2003047552A2 (es) |
| ZA (1) | ZA200403849B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
| US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
| JP2006522790A (ja) * | 2003-04-11 | 2006-10-05 | ファイザー・インク | エレトリプタンと重炭酸ナトリウムを含む医薬組み合わせ物 |
| BRPI0410807A (pt) * | 2003-06-06 | 2006-06-27 | Glaxo Group Ltd | composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica |
| WO2005115345A1 (en) * | 2004-05-28 | 2005-12-08 | Imaginot Pty Ltd | Oral therapeutic compound delivery system |
| US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| WO2006047493A2 (en) | 2004-10-21 | 2006-05-04 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| WO2007059591A1 (en) | 2005-11-28 | 2007-05-31 | Imaginot Pty Ltd | Oral therapeutic compound delivery system |
| RU2313340C1 (ru) * | 2006-02-20 | 2007-12-27 | Дмитрий Владимирович Зимин | Лекарственное средство, обладающее противомигренозным действием, и способ его изготовления |
| WO2007130373A2 (en) * | 2006-05-01 | 2007-11-15 | Capricorn Pharma, Inc. | Novel triptan formulations and methods for making them |
| WO2008039358A2 (en) * | 2006-09-30 | 2008-04-03 | Capricorn Pharma Inc. | Resin-complex granulation for water-soluble drugs and associated methods |
| RU2424803C2 (ru) * | 2008-04-07 | 2011-07-27 | Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН (НИИ фармакологии имени В.В.Закусова РАМН) | Фармацевтическая композиция с противомигреневым действием (варианты) |
| MX2012006240A (es) | 2009-12-02 | 2012-10-03 | Aptalis Pharma Ltd | Microcapsulas de fexofenadina y composiciones que contienen las mismas. |
| US11364225B2 (en) | 2019-08-21 | 2022-06-21 | Bn Intellectual Properties, Inc. | Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same |
| IL297218A (en) * | 2020-04-24 | 2022-12-01 | Astrazeneca Ab | Pharmaceutical formulations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9027827D0 (en) * | 1990-12-21 | 1991-02-13 | Glaxo Laboratoires | Pharmaceutical compositions |
| US5468504A (en) * | 1990-12-21 | 1995-11-21 | Laboratoires Glaxo S.A. | Effervescent pharmaceutical compositions |
| GB9104890D0 (en) * | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
| US5460972A (en) * | 1991-04-08 | 1995-10-24 | Research Foundation Of The State University Of New York | Ionized magnesium2+ concentrations in biological samples |
| US6649186B1 (en) * | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
| GB9704524D0 (en) * | 1997-03-05 | 1997-04-23 | Smithkline Beecham Plc | Composition |
| GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
| WO1999043306A1 (en) * | 1998-02-26 | 1999-09-02 | Banyu Pharmaceutical Co., Ltd. | An orally disintegrating composition and its manufacturing method |
| US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| CA2392810A1 (en) * | 1999-12-01 | 2001-06-07 | Natco Pharma Limited | A rapid acting freeze dired oral pharmaceutical composition for treating migraine |
| KR20010107754A (ko) * | 2000-05-26 | 2001-12-07 | 민경윤 | 경구투여용 속용정의 제조 방법 |
| US20030008005A1 (en) * | 2001-07-05 | 2003-01-09 | R.T. Alamo Ventures, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
-
2001
- 2001-12-05 GB GBGB0129117.8A patent/GB0129117D0/en not_active Ceased
-
2002
- 2002-12-03 AR ARP020104674A patent/AR037627A1/es unknown
- 2002-12-03 MY MYPI20024534A patent/MY129314A/en unknown
- 2002-12-03 FI FI20022128A patent/FI20022128A7/fi not_active Application Discontinuation
- 2002-12-03 TW TW091134979A patent/TWI240638B/zh not_active IP Right Cessation
- 2002-12-03 NO NO20025805A patent/NO329896B1/no not_active IP Right Cessation
- 2002-12-04 IL IL16199702A patent/IL161997A/xx active IP Right Grant
- 2002-12-04 RU RU2004120292/15A patent/RU2285526C2/ru not_active IP Right Cessation
- 2002-12-04 ES ES02792887T patent/ES2236608T3/es not_active Expired - Lifetime
- 2002-12-04 WO PCT/EP2002/013715 patent/WO2003047552A2/en not_active Ceased
- 2002-12-04 AT AT02792887T patent/ATE291900T1/de active
- 2002-12-04 PL PL02370669A patent/PL194702B1/pl unknown
- 2002-12-04 AU AU2002358602A patent/AU2002358602B2/en not_active Expired
- 2002-12-04 DE DE60203537T patent/DE60203537T2/de not_active Expired - Lifetime
- 2002-12-04 CN CNB028244184A patent/CN1289069C/zh not_active Expired - Fee Related
- 2002-12-04 CA CA002469019A patent/CA2469019C/en not_active Expired - Lifetime
- 2002-12-04 US US10/497,749 patent/US20050032867A1/en not_active Abandoned
- 2002-12-04 JP JP2003548808A patent/JP3699969B2/ja not_active Expired - Lifetime
- 2002-12-04 PT PT02792887T patent/PT1450770E/pt unknown
- 2002-12-04 EP EP02792887A patent/EP1450770B1/en not_active Expired - Lifetime
- 2002-12-04 KR KR1020047008687A patent/KR100591237B1/ko not_active Expired - Lifetime
- 2002-12-04 BR BR0214497-2A patent/BR0214497A/pt not_active Application Discontinuation
- 2002-12-04 MX MXPA04005420A patent/MXPA04005420A/es active IP Right Grant
- 2002-12-04 HU HU0402178A patent/HU229313B1/hu unknown
- 2002-12-04 NZ NZ532829A patent/NZ532829A/en not_active IP Right Cessation
- 2002-12-04 EP EP05075288A patent/EP1527773A1/en not_active Withdrawn
-
2004
- 2004-05-19 ZA ZA2004/03849A patent/ZA200403849B/en unknown
- 2004-06-03 CO CO04052110A patent/CO5580741A2/es active IP Right Grant
- 2004-06-03 IS IS7293A patent/IS2481B/is unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037627A1 (es) | Composicion farmaceutica en forma de dosificacion solida para su administracion oral y uso de dicha composicion farmaceutica y de un componente basico de una pareja efervescente para la fabricacion de un medicamento | |
| JP2023134518A (ja) | 透過性増強された医薬組成物 | |
| ES2520990T3 (es) | Composiciones farmacéuticas que comprenden derivados de 2-oxo-1-pirrolidina | |
| DE60032749D1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| EA201190012A1 (ru) | Твердые лекарственные формы бендамустина | |
| PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
| JPWO2002096406A1 (ja) | 医薬組成物 | |
| CA2535803A1 (en) | Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof | |
| JP2024507991A (ja) | 激越を処置するための方法及び組成物 | |
| ES2282062T1 (es) | Composicion farmaceutica que contiene irbesartan. | |
| JP4106232B2 (ja) | 医薬組成物 | |
| PT2448561E (pt) | Composições farmacêuticas sólidas de dose fixa compreendendo irbesartan e amlodipina, sua preparação e seu aplicação terapêutica | |
| JP2005154437A (ja) | トラニラスト含有医薬組成物 | |
| RU2010121919A (ru) | Диспиро 1, 2, 4-триоксоланы как противомалярийные средства | |
| WO2023187599A1 (en) | Methods and bioavailable highly permeable compounds for the treatment of viral diseases | |
| EP4358943A1 (en) | Naltrexone for boosting the therapeutic utility of 5-ht receptor agonists | |
| US20080242717A1 (en) | Methods for treating benign prostatic hyperplasia | |
| BR112020012157A2 (pt) | composição farmacêutica oral de um antagonista de nk-1 | |
| JP4632687B2 (ja) | 点鼻剤 | |
| CN105250316A (zh) | 一种含二联苯酚的抗癫痫药物组合 | |
| KR20200131913A (ko) | 플루르비프로펜을 포함하는 약학적 조성물 | |
| JP5468351B2 (ja) | 経口用医薬組成物 | |
| ES2443968T3 (es) | Composiciones farmacéuticas de olmesartán | |
| JP5329866B2 (ja) | 医薬組成物及び関節障害の予防治療剤 | |
| JP5054966B2 (ja) | 固形製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |